U.S. markets closed

Exagen Inc. (XGN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.9800-0.0700 (-1.39%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close5.0500
Bid1.9800 x 800
Ask6.7400 x 900
Day's Range4.8400 - 5.2060
52 Week Range4.1500 - 14.9000
Avg. Volume56,533
Market Cap80.977M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-1.8200
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for XGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exagen Inc.
    Daily – Vickers Top Buyers & Sellers for 11/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Motley Fool

    Exagen Inc. (XGN) Q2 2022 Earnings Call Transcript

    Earlier today, Exagen Inc. released financial results for the quarter ended June 30th, 2022. Ron Rocca, president and chief Executive officer; Kamal Adawi, chief financial officer; Mark Hazeltine, chief operating officer, will host this afternoon's call. Before we get started, I'd like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

  • Zacks

    Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates

    Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

    SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic diagnostic test for rheumatoid arthritis using the AVISE® RADR platform. The goal of the Treatment stratIfication using Gene Expression profiling in Rheumatoid arthritis (TiGER) study is to assess whether certain biomarkers from synovial biopsies of inflame